Follow us on :



Take a look at the Recent articles

Lenalidomide induced stroke in multiple myeloma

Shridhar P

Department of Bioengineering, University of Pittsburgh, Pittsburgh, USA

E-mail : PUS8@pitt.edu

Khalil R

Department of Cardiology, Allegheny General Hospital, Pittsburgh, USA

Lasorda D

Department of Cardiology, Allegheny General Hospital, Pittsburgh, USA

Chun Y

Department of Bioengineering, University of Pittsburgh, Pittsburgh, USA

Department of Industrial Engineering, University of Pittsburgh, Pittsburgh, USA

McGowan Institute for Regenerative Medicine, Pittsburgh, USA

DOI: 10.15761/JIC.1000184

Article
Article Info
Author Info
Figures & Data

Mini- Review

Lenalidomide (Revlimid) is a novel agent used in treatment of multiple myeloma (MM) with an adverse effect of thromboembolic episodes, more commonly, deep vein thrombosis and pulmonary embolism [1]. Venous thromboembolism has emerged as one of the leading complications of the life saving drug [2]. In addition, there is an increased burden of Lenalidomide induced stroke and myocardial infarction [3,4]. Recently, the antiangiogenic agents, in general, and Lenalidomide in particular have been associated with stroke [5,6]. Furthermore, it was hypothesized that Lenalidomide, a Thalidomide analog, induces less neurotoxicity compared to thalidomide [7,8].

Tannemaat et al. reported an instance where a relatively young female suffered from stroke in one week after the administration of Lenalidomide in the absence of other risk factors [9]. In the Chavez study, a patient died within 30 days of active treatment with Lenalidomide due to an acute ischemic stroke [10]. In another instance, Scarpace et al. described one instance of transient ischemic attack (TIA) and two ischemic strokes treated with thalidomide 4 to 5 years after diagnosis of MM [11,12]. In addition, sudden death speculated due to stroke secondary to Lendalidomide has also been cited in literature [13]. This indicates that stroke, a dreadful complication of life changing drug can strike anytime (days, weeks, years) during treatment. There is an indication that intra-arterial light chain depositions may be responsible for the ischemic cerebrovascular events in these patients [9].

It can be seen both elderly and young adults, with increased frequency in newly diagnosed MM cases [2]. Clinical presentation can show considerable variation ranging from isolated headache to severe intracranial hypertension, hemiparesis, seizures, and encephalopathy. The severity of the complication may vary from reversible TIA to possible sudden death. An improvement of neurological symptoms is usually observed within 3–4 months after cessation of treatment with Thalidomide [14]. This can be compared with cisplatin which results in arterial ischemia and stroke which are more frequent within 10 days of treatment and following the first cycle of chemotherapy [15]. Similarly, intra-CSF or intravenous high-dose methotrexate, cyclophosphamide, 5-FU result in arterial ischemia. L-asparaginase on the other hand leads to hemorrhagic venous stroke mostly secondary to superior sagittal sinus or cortical vein thrombosis [16].

Adverse drug event reports received by US Food and Drug Administration (FDA) noted that Lenalidomide for multiple myeloma was among the largest number of incomplete reports with the sole event term death in 2014 (n=717) [15]. The stroke risk increases with immunomodulators like Lenalidomide, further still with combination therapy of Lenalidomide with corticosteroids and the maximum risk is associated with a combination therapy of Lenalidomide and alkylating agents like doxorubicin [17]. An increased incidence of TEEs in 1 arm became apparent: 75% patients receiving dexamethasone and Lenalidomide developed thromboembolic events (along with 1 ischemic stroke) after a median of 50 days, versus 0% on dexamethasone alone (P<.001) [18,19]. In the long-term follow-up of 704 patients with MM in 2 phase 3, randomized, clinical trials, the incidence of cerebrovascular events was 3.4%, in patients treated with Lenalidomide and dexamethasone compared with 1.7%, in patients treated with dexamethasone alone [20]. A phase 1/2 study of Lenalidomide with vorinostat and dexamethasone, reported maximum tolerated dose was only 5 mg/day due to patients experiencing grade 3 thrombocytopenia and grade 4 stroke [21].  

It is recommended that all patients on Lenalidomide and high dose (dexamethasone/doxorubicin) should receive anticoagulation with either LMWH or full dose Warfarin with target INR of 2-3. According to recommendation from International Myeloma Working Group (IMWG), LMWH for all patients receiving Lenalidomide and high-dose dexamethasone or doxorubicin and suggests that full-dose warfarin may be an alternative to LMWH. However, this was in the absence of clear data from randomized studies [9]. In a multi-center prospective, open label phase I/II trial, thromboembolic episodes including grade 4 stroke occurred despite LMWH administration to all patients [24]. Due to the lack of prospective randomized clinical trials, different studies have used various anticoagulant prophylaxes, including fixed low-dose warfarin (1 mg or 1.25 mg), therapeutic doses of warfarin (international normalized ratio between 2.0 and 3.0), low molecular weight heparin, or low-dose aspirin [2]. As yet, no study has clearly demonstrated a significant superiority of one prophylactic regimen LMWH or full-dose warfarin effectively reduce the risk of VTEs.

In our experience, if the patient’s INR was at target, we elected to maintain him on daily Plavix and monitor INR on regular basis. In patients who received prophylaxis with aspirin genetic variants of genes that are involved directly or indirectly in inflammatory response may be associated with increased risk of VTE [25]. Cohen et al. concluded that the benefits of aspirin are well documented for conditions like myocardial infarction and stroke [22]. It is well established that aspirin is effective in reducing the risk of myocardial infarction and stroke, but its role in reducing venous thrombosis is controversial [23]. A retrospective series of 83 patients who were treated with Lenalidomide containing regimens showed asymptomatic venous thromboembolic event occurred in 18% despite aspirin prophylaxis. The authors further recommended serial monitoring of plasma D-dimer levels and early intervention may help to prevent symptomatic or lethal VTE events [26]. Moreover, ribavirin as a potential antithrombotic agent has also been suggested [27].

It is not uncommon for patients with plasma cell dyscrasias have a higher incidence of thromboembolic events associated with increased production of inflammatory cytokines such as CRP, IL-6 and TNF, procoagulant factors such as factor VIII and Von Willebrand factor, protein C resistance [28]. In addition, Lenalidomide initiation in Myelodysplastic Syndrome with 5q deletion was found to be negatively associated with stroke [29]. It is very important that physicians should be aware Lenalidomide carries a black box warning of significant stroke risks in patients with MM receiving Lenalidomide and dexamethasone treatment [30]. Increased vigilance from clinicians for stroke or myocardial infarction is highly recommended in patients with multiple myeloma.

References

  1. Cruz MP (2016) Lenalidomide (Revlimid): A thalidomide analogue in combination with dexamethasone for the treatment of all patients with multiple myeloma. P T 41: 308-313. [Crossref]
  2. Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, et al. (2011) Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 37: 209-219. [Crossref]
  3. Singh A, Gajra A (2011) Thromboembolism with immunomodulatory agents in patients with multiple myeloma. Cardiovascular & Hematological Agents in Medical Chemistry 9:7-13
  4. Lee GY, Lee YT, Yeh CM, et al. (2016) Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study. Hematol Oncol . [Crossref]
  5. Ortín X, Rodríguez-Luaces M, Calabuig M, Font L (2006) Stroke in a multiple myeloma patient treated with thalidomide. Journal of Stroke and Cerebrovascular Diseases 15:283–285.
  6. Dearborn JL, Urrutia VC, Zeiler SR (2014) Stroke and cancer- a complicated relationship. J Neurol Transl Neurosci 2: 1039. [Crossref]
  7. Grisold W, Cavaletti G, Windebank AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14 Suppl 4: iv45-54. [Crossref]
  8. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, et al. (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115: 1343-1350. [Crossref]
  9. Tannemaat MR, Vries EP, Molendijk WJ, Haan J (2011) Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma. Clin Neurol Neurosurg 113: 488-489. [Crossref]
  10. Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E et al (2016). Results of a phase II study of Lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leukemia Research 47:78-83.
  11. Scarpace SL, Hahn T, Roy H, Brown K, Paplham P, et al (2005). Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 46:239–242.
  12. Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW (2010) High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 116: 22-26. [Crossref]
  13. Finsterer J, Höftberger R, Stöllberger C, Wöhrer A, Regele H (2013). Sudden death possibly related to Lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease. Journal of Oncology Pharmacy Practice 19:170-4.
  14. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, et al. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021-1030. [Crossref]
  15. Moore TJ, Furberg CD, Mattison DR, Cohen MR (2016). Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiology and drug safety.
  16. Taillibert S, Le Rhun E, Chamberlain MC (2016) Chemotherapy-related neurotoxicity. Curr Neurol Neurosci Rep 16: 81. [Crossref]
  17. Weiss L, Shah K, Yiu W, Freeman J, Knight R, et al. (2009) Overview of venous thromboembolism (VTE) in nearly 100,000 patients treated with Revlimid®(Lenalidomide). Blood 114: 2881
  18. Zonder JA, Durie BG, McCoy J, Crowley J, Zeldis JB, et al. (2005) High incidence of thrombotic events observed in patients receiving Lenalidomide (L)+ Dexamethasone (D)(LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. Blood 106.
  19. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, et al. (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with Lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108: 403-404.
  20. Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, et al. (2016) cardiovascular complications of novel multiple myeloma treatments. Circulation 133: 908-912. [Crossref]
  21. Toumishey E, Prasad A, Dueck G, Chua N, Finch D, et al. (2015) Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 121: 716-723. [Crossref]
  22. Borgdorff P, Tangelder GJ2 (2016) Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism. Thromb Res 139: 121-124.
  23. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A (2008) Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112: 1522-1528. [Crossref]
  24. Hopfinger G, Nösslinger T, Lang A, Linkesch W, Melchardt T, et al. (2014) Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann Hematol 93: 459-462. [Crossref]
  25. Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, et al. (2013). Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with Lenalidomide-based regimens. American journal of hematology 88: 765-770.
  26. Isoda A, Sato N, Miyazawa Y, Matsumoto Y, Koumoto M, et al. (2015) Silent venous thromboembolism in multiple myeloma patients treated with Lenalidomide. International journal of hematology 102: 271-277.
  27. Kamat AV (2014) Rivaroxaban is an effective and well tolerated anti thrombotic agent in patients on lenalidomide therapy and in multiple Myeloma. Blood 124: 5095.
  28. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, et al. (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414-423. [Crossref]
  29. Zeidan AM, Gore SD, McNally DL, Baer MR, Hendrick F, et al. (2013) Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer 119: 3870-3878. [Crossref]
  30. Lenalidomide (Revlimid) black box warning.

 

Editorial Information

Editor-in-Chief

Massimo Fioranelli
Guglielmo Marconi University

Article Type

Mini Review

Publication history

Received: September 05, 2016
Accepted: September 16, 2016
Published: September 20, 2016

Copyright

©2016 Shridhar P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation

Shridhar P, Khalil R, Lasorda D and Chun (2016) Lenalidomide induced stroke in multiple myeloma. J Integr Cardiol 2: DOI: 10.15761/JIC.1000184

Corresponding author

Puneeth Shridhar

Department of Bioengineering, University of Pittsburgh, Pittsburgh, USA

E-mail : PUS8@pitt.edu

No Data.